drugset / Trial / NCT00642291

An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects

NCT00642291

Phase 2 Completed 16 enrolled Gilead Sciences
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To obtain safety and efficacy data for antiretroviral regimens containing emtricitabine in HIV-1 infected pediatric subjects. To determine emtricitabine concentrations in HIV-1 infected pediatric subjects and, if necessary, to refine the dose of emtricitabine to achieve concentrations comparable to those in adults given 200 mg emtricitabine once-daily.

Timeline

Start
2002-11
Primary completion
2004-07
Completion
2004-07

Drugs

EvaluationDrugModalityDoseRoute
Subject emtricitabine Other / unclassified 6 mg/kg Oral